Chapter 1060： Cost is priceless (1/2)

”Pick up an apocalyptic world (

In the third batch of quotations, there are many top pharmaceutical companies in it, and even many individuals in it.

Many of these pharmaceutical companies have obtained exclusive agency rights in the first and second rounds of auctions, but they still have not stopped competing for exclusive agency rights in other regions.

For a company like Ito Group, 2.5 billion US dollars have been spent. Do you still care about 100 million US dollars?

As long as the exclusive agency rights in a certain region are obtained, it means that another batch of general cancer treatment drugs can be obtained.

After getting the general cancer medicine, who knows where these general cancer medicines are used?

For this loophole, does Xingchen Pharmaceutical know about it?

Of course I know, but Star Pharma has not stopped their practices. They compete with each other, and it is Star Pharma that ultimately benefits. Why don't you make money if you have money?

For those top group companies competing for the third batch, as long as they win exclusive agency rights in a certain region, their costs will be much lower.

Almost all of these things are on the facade, and anyone can participate.

The third and final batch, although the number is large, the competition is quite fierce.

At the last minute, the bidding prices of various countries had almost doubled, and the lowest prices had exceeded 200 million US dollars.

In the last minute, the bidding numbers scrolled wildly, and it was almost impossible to see what the price was.

No one knows what the final transaction price will be.

Even the top groups dare not assert that they will be able to win exclusive agency rights in a certain region.

Too much, it feels a bit unworthy, and less, it is a bit uncomfortable to be snatched away.

Ding.

The third batch of transaction prices are freshly released.

Everyone was stunned by the price in front of them.

The highest in a country, reached 635 million US dollars.

It is necessary to know that the price in the second round is only half a billion US dollars, and the 635 million US dollars is more than 100 million US dollars more than the second round price. You can see the crazy behavior of these investors.

The difference between the second and third rounds of exclusive agency rights lies in the supply of general cancer treatment drugs.

The annual supply of the first round of general cancer treatment drugs is 1,200 copies.

The annual supply of the second round of general cancer treatment drugs is 600 copies.

The supply of the third round of general-purpose cancer drugs in one year is only 300 copies.

The cost of the exclusive agency fee was evenly divided among each generic cancer drug, and the price was doubled.

However, there are not many of the third round of over 500 million US dollars, most of which are around 300 million US dollars.

The lowest one is only $265 million.

Three rounds of exclusive agency auctions ended successfully.

This auction lasted for three hours, but the turnover exceeded 100 billion US dollars.